raising questions about FDA's drug approval and surveillance process

A firestorm of press is raising questions about FDA's drug approval and surveillance process.

It started with the Vioxx revelations. Then an FDA insider fueled the fires with congressional testimony naming several more drugs with safety concerns.

Crestor (rosuvastatin) is under scrutiny for rhabdomyolysis and renal failure. FDA is keeping a close eye on it. For now, avoid high doses...especially in patients over 65, with severe renal insufficiency, or those taking gemfibrozil or cyclosporine.